Abstract
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy, presenting significant clinical heterogeneity. Arrhythmia risk stratification and detection are critical components in the evaluation and management of all cases of HCM. The 2020 American Heart Association/American College of Cardiology HCM guidelines provide new recommendations for periodic 24-48-hour ambulatory electrocardiogram monitoring to screen for atrial and ventricular arrhythmias. A strategy of more frequent or prolonged monitoring would lead to earlier arrhythmia recognition and the potential for appropriate treatment. However, whether such a strategy in patients with HCM results in improved outcomes is not yet established. The available evidence, knowledge gaps, and potential merits of such an approach are reviewed. Cardiac implantable electronic devices provide an opportunity for early arrhythmia detection, with the potential to enable early management strategies in order to improve outcomes.